Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex

J Clin Microbiol. 2009 Nov;47(11):3630-4. doi: 10.1128/JCM.00803-09. Epub 2009 Sep 9.

Abstract

The Bactec MGIT 960 system for testing susceptibility to second-line drugs was evaluated with 117 clinical strains in a multicenter study. The four drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide. The critical concentration established for levofloxacin and amikacin was 1.5 microg/ml, that established for capreomycin was 3.0 microg/ml, and that established for ethionamide was 5.0 microg/ml. The overall level of agreement between the agar proportion method and the MGIT 960 system was 96.4%, and the levels of agreement for the individuals drugs were 99.1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide. The rate of reproducibility of the drug susceptibility testing results between the participating laboratories was 99.5%.

Publication types

  • Evaluation Study
  • Multicenter Study

MeSH terms

  • Amikacin / pharmacology
  • Antitubercular Agents / pharmacology*
  • Capreomycin / pharmacology
  • Ethionamide / pharmacology
  • Humans
  • Levofloxacin
  • Microbial Sensitivity Tests / methods*
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Ofloxacin / pharmacology
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tuberculosis / microbiology

Substances

  • Antitubercular Agents
  • Capreomycin
  • Levofloxacin
  • Amikacin
  • Ofloxacin
  • Ethionamide